| The effect of genetic variants of SLC22A18 on proliferation, migration, and invasion of colon cancer cells. | The effect of genetic variants of SLC22A18 on proliferation, migration, and invasion of colon cancer cells.
Song HS, Ha SY, Kim JY, Kim M, Choi JH., Free PMC Article | 03/1/2024 |
| These results suggest that SLC22A18 may act as a tumor suppressor by regulating the expression levels of cell growth-related proteins, and vinca alkaloids might show therapeutic efficacy against low-SLC22A18-expressing breast cancer. | Involvement of an Orphan Transporter, SLC22A18, in Cell Growth and Drug Resistance of Human Breast Cancer MCF7 Cells.
Ito S, Fujino Y, Ogata S, Hirayama-Kurogi M, Ohtsuki S. | 08/17/2019 |
| suppression of SLC22A18 decreased the supply of intracellular free fatty acids from triglyceride-rich lipid droplets by impairing the lysosomal/autophagy degradation pathway and reduced the invasive activity of HepG2 cells by decreasing IGFBP-1 expression | Knockdown of Orphan Transporter SLC22A18 Impairs Lipid Metabolism and Increases Invasiveness of HepG2 Cells.
Ito S, Honda G, Fujino Y, Ogata S, Hirayama-Kurogi M, Ohtsuki S. | 01/26/2019 |
| Data provide evidence that SLC22A18 and/or CDKN1C are tumor modifier genes involved in the tumorigenesis of SDHD-mutated paraganglioma. | Parent-of-origin tumourigenesis is mediated by an essential imprinted modifier in SDHD-linked paragangliomas: SLC22A18 and CDKN1C are candidate tumour modifiers.
Hoekstra AS, Addie RD, Ras C, Seifar RM, Ruivenkamp CA, Briaire-de Bruijn IH, Hes FJ, Jansen JC, Corssmit EP, Corver WE, Morreau H, Bovée JV, Bayley JP, Devilee P. | 08/26/2017 |
| Establish SLC22A18 as a tumor suppressor in colon epithelial cells and propose that SLC22A18 is potentially a marker of diagnostic and prognostic values. | Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancer.
Jung Y, Jun Y, Lee HY, Kim S, Jung Y, Keum J, Lee YS, Cho YB, Lee S, Kim J., Free PMC Article | 07/30/2016 |
| microRNA-137 functions as a tumor suppressor in human non-small cell lung cancer by targeting SLC22A18 | microRNA-137 functions as a tumor suppressor in human non-small cell lung cancer by targeting SLC22A18.
Zhang B, Liu T, Wu T, Wang Z, Rao Z, Gao J. | 11/21/2015 |
| Upregulated expression of SLC22A18 enhanced the radiosensitivity of glioma U251 cells. | In vitro and in vivo radiosensitization of human glioma U251 cells induced by upregulated expression of SLC22A18.
Chu SH, Zhou ZM, Karri S, Li ZQ, Zhao JM. | 12/20/2014 |
| SLC22A18 protein expression predicted a significantly shorter overall survival in 51 patients receiving TMZ therapy, whereas no differences in overall survival were observed in 35 patients without TMZ therapy | Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy.
Chu SH, Ma YB, Feng DF, Li ZQ, Jiang PC., Free PMC Article | 08/10/2013 |
| SLC22A18 functions as a tumor suppressor in glioma and represents a candidate biomarker for long-term survival in this disease. | Correlation of low SLC22A18 expression with poor prognosis in patients with glioma.
Chu SH, Ma YB, Feng DF, Zhang H, Zhu ZA, Li ZQ, Jiang PC. | 07/7/2012 |
| The expression level of SLC22A18 in non-small cell lung cancer was significantly higher than that in normal tissue. | [Expression and its clinical significance of SLC22A18 in non-small cell lung cancer].
Lei M, Cheng Q, Zhao Y, Liu T, Wang X, Deng Y, Yang J, Zhang Z., Free PMC Article | 05/5/2012 |
| SLC22A18 downregulation via promoter methylation is associated with the development and progression of glioma. | Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma.
Chu SH, Feng DF, Ma YB, Zhang H, Zhu ZA, Li ZQ, Jiang PC., Free PMC Article | 01/21/2012 |
| Low expression of SLC22A18 was associated with tumor progression, recurrence and poor survival after breast surgery | Low expression of SLC22A18 predicts poor survival outcome in patients with breast cancer after surgery.
He H, Xu C, Zhao Z, Qin X, Xu H, Zhang H. | 09/17/2011 |
| SLC22A18 gene is imprinted, with preferential expression from the maternal allele. | Somatic mutation of TSSC5, a novel imprinted gene from human chromosome 11p15.5.
Lee MP, Reeves C, Schmitt A, Su K, Connors TD, Hu RJ, Brandenburg S, Lee MJ, Miller G, Feinberg AP. | 10/26/2010 |
| Observational study and genome-wide association study of gene-disease association. (HuGE Navigator) | Genome-wide association study of alcohol dependence implicates a region on chromosome 11.
Edenberg HJ, Koller DL, Xuei X, Wetherill L, McClintick JN, Almasy L, Bierut LJ, Bucholz KK, Goate A, Aliev F, Dick D, Hesselbrock V, Hinrichs A, Kramer J, Kuperman S, Nurnberger JI Jr, Rice JP, Schuckit MA, Taylor R, Todd Webb B, Tischfield JA, Porjesz B, Foroud T., Free PMC Article | 04/7/2010 |
| Mutational analysis of the two Sp1 sites suggested their requirement for the promoter activityof SLC22A18. | Characterization of the human SLC22A18 gene promoter and its regulation by the transcription factor Sp1.
Ali AM, Bajaj V, Gopinath KS, Kumar A, Ali AM, Bajaj V, Gopinath KS, Kumar A. | 01/21/2010 |
| recent demonstration that the promoter of this gene is positively regulated by Sp1 | Characterization of the human SLC22A18 gene promoter and its regulation by the transcription factor Sp1.
Ali AM, Bajaj V, Gopinath KS, Kumar A, Ali AM, Bajaj V, Gopinath KS, Kumar A. | 02/25/2009 |
| UbcH6-RING105 may define a novel ubiquitin-proteasome pathway that targets TSSC5 in mammalian cells | Tumor suppressor candidate TSSC5 is regulated by UbcH6 and a novel ubiquitin ligase RING105.
Yamada HY, Gorbsky GJ., Free PMC Article | 01/21/2010 |
| study reports the imprinting status of SLC22A18AS in breast tissue and breast cancer, and shows that gain of imprinting affects both the sense, and antisense transcripts at this locus | Gain of imprinting of SLC22A18 sense and antisense transcripts in human breast cancer.
Gallagher E, Mc Goldrick A, Chung WY, Mc Cormack O, Harrison M, Kerin M, Dervan PA, Mc Cann A. | 01/21/2010 |
| involved in the drug resistance mechanism of tumors | [Mechanisms of drug resistance and reversal of the resistance].
Akiyama S. | 01/21/2010 |